NAD Supplementation in Parkinson's Disease

What Was Tested

The trial (not phased) is built around NAD+ for parkinson's disease.

NR is considered investigational for this study because it is not yet established for this specific use.

It had two arms (groups): Active intervention (active comparator) and Placebo intervention (placebo comparator).

Participants assigned to the placebo arm will take an oral placebo capsule daily for 12 weeks. The placebo will appear identical to the nicotinamide riboside capsules.

The registry classes the interventions as dietary supplement.

More on the Plan

This is a single-site, randomized, placebo-controlled clinical trial evaluating oral nicotinamide riboside (NR), a form of vitamin B3, in adults over 55 years of age with Parkinson's disease.

NR is commercially available as a dietary supplement, however, its use in this study for Parkinson's disease is considered investigational because it is not approved by the U.S.

Food and Drug Administration as a treatment for Parkinson's disease.

Neither the participants nor the investigators will choose the assigned group.

Who Took Part

The registry lists 40 planned participants were the target.

It was open to people of any sex aged from 55 years up to 85 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Clinical diagnosis of Parkinson's disease according to Movement Disorder Society clinical diagnostic criteria (59), Hoehn and Yahr stages I-III at enrollment (ON medication state when applicable) (60). Age ≥55 years at enrollment. Adequate hearing and visual acuity to participate in the examinations. Ability to provide written informed consent in English. Ability to complete study procedures, including seated tasks and walking tasks (with or without an assistive device, if needed for safety).

The full record lists 6 inclusion and 8 exclusion criteria; among the exclusions: not able to communicate or follow instructions due to aphasia or severe cognitive impairment; active cns disease including multiple sclerosis, uncontrolled seizures, active cancer; cerebrovascular accident other than tia within 60 days prior to visit 0.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The NAD+ group and the comparison group ran side by side rather than switching.

Neither the parkinson's disease participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-08-10 with completion listed for 2027-07.

It ran at 1 site in United States.

Its stated primary purpose is prevention.

What Was Measured

Primary outcome: Change in task-evoked neurovascular coupling response measured by functional near-infrared spectroscopy (time frame: Baseline to 12 weeks).

It also tracked 5 secondary outcomes, for example Change in NIH Toolbox Cognitive Battery score, Change in timed walking test completion, Change in gait speed during single and dual-task walking, Change in handgrip strength and Change in static balance performance.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 40 people with parkinson's disease.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, Parkinson's disease research.